Market Overview

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients

Share:





Novocure™ (NASDAQ:NVCR) announced today results from health-related
quality of life analyses from its phase 3, pivotal EF-14 trial adding
Optune to standard temozolomide chemotherapy for the treatment of newly
diagnosed glioblastoma. The data, presented at this year's World
Federation of Neuro-oncology Societies 5th Quadrennial
Meeting in Zurich, showed that Optune with temozolomide did not
negatively impact health-related quality of life, except for itchy skin,
which was most likely due to skin irritation beneath Optune's transducer
arrays. The combination treatment of Optune with temozolomide improved
deterioration-free survival of several predefined health-related quality
of life scales, compared to temozolomide alone, likely related to
improved progression free and overall survival.

"Some physicians and patients have expressed concerns regarding the
possible negative impact of Optune on patient quality of life" said
Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of
Research and Development. "The health-related quality of life analyses
presented this weekend show conclusively that not only was quality of
life not harmed by the use of Optune with temozolomide but deterioration
in quality of life was delayed compared to temozolomide alone in several
health related quality of life scales, most likely due to the longer
progression free and overall survival of patients treated with Optune
with temozolomide."

Patients completed two validated health-related quality of life
questionnaires (EORTC QLQ-C30 and BN20) at the beginning of the trial,
and every three months thereafter. Health-related quality of life over
time was assessed for nine preselected scales: global health, physical,
cognitive, role, social and emotional functioning, itchy skin, pain and
weakness of legs. The results were as follows:

  • More patients treated with the combination of Optune and temozolomide
    reported stable or improved scores on: global health status (53
    percent versus 38 percent, p=.001), pain (57 percent versus 36
    percent, p<.0001), physical functioning (54 percent versus 38 percent,
    p=.001) and leg weakness (59 percent versus 42 percent, p=.001) when
    compared to patients treated with temozolomide alone.
  • Deterioration-free survival (the time until quality of life declined
    by more than 10 points or disease progression) was longer (p<.01) for
    patients treated with the combination of Optune and temozolomide
    versus patients treated with temozolomide alone for: global health
    (4.8 versus 3.3 months), physical (5.1 versus 3.7 months) and
    emotional functioning (5.3 versus 3.9 months), pain (5.6 versus 3.6
    months) and leg weakness (5.6 versus 3.9 months).
  • Time to deterioration (the time until quality of life declined by more
    than 10 points, excluding disease progression) did not significantly
    differ between treatment arms, except for itchy skin (8.2 months for
    patients treated with Optune plus temozolomide versus 14.4 months for
    patients treated with temozolomide alone, p<.001), and pain (13.4
    months for patients treated with Optune plus temozolomide versus 12.1
    months for patients treated with temozolomide alone, p<.001).
  • Health-related quality of life over time did not significantly differ
    between treatment arms except for itchy skin, which was worse with
    Optune plus temozolomide versus temozolomide alone, at three, six and
    nine months (p=.0004).

"This data further cements our belief that Optune plus temozolomide
should be offered as an essential combination therapy to every newly
diagnosed patient with glioblastoma," said Asaf Danziger, Novocure's
CEO. "We are pleased to offer a treatment that may not only provide a
survival benefit in terms of duration of life but also has the potential
to provide stability or improvement in the quality of life during that
time compared to the use of temozolomide alone."

About Novocure

Novocure is an oncology company developing a profoundly different cancer
treatment centered on a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure's commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating TTFields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and a research
center in Israel. For additional information about the company, please
visit www.novocure.com
or follow us at www.twitter.com/novocure.

Approved Indications

In the United States, Optune is intended as a treatment for adult
patients (22 years of age or older) with histologically-confirmed
glioblastoma multiforme (GBM).

In the United States, Optune with temozolomide is indicated for the
treatment of adult patients with newly diagnosed, supratentorial
glioblastoma following maximal debulking surgery and completion of
radiation therapy together with concomitant standard of care
chemotherapy.

In the United States, for the treatment of recurrent GBM, Optune is
indicated following histologically-or radiologically-confirmed
recurrence in the supratentorial region of the brain after receiving
chemotherapy. The device is intended to be used as a monotherapy, and is
intended as an alternative to standard medical therapy for GBM after
surgical and radiation options have been exhausted.

In the European Union, Optune is intended for the treatment of patients
with newly diagnosed GBM, after surgery and radiotherapy with adjuvant
temozolomide, concomitant to maintenance temozolomide. The treatment is
intended for adult patients, 18 years of age or older, and should be
started more than 4 weeks after surgery and radiation therapy with
adjuvant temozolomide. Treatment may be given together with maintenance
temozolomide and after maintenance temozolomide is stopped.

In the European Union, Optune is also intended for the treatment of
patients with recurrent GBM who have progressed after surgery,
radiotherapy and temozolomide treatment for their primary disease. The
treatment is intended for adult patients, 18 years of age or older, and
should be started more than 4 weeks after the latest surgery, radiation
therapy or chemotherapy.

Patients should only use Optune under the supervision of a physician
properly trained in use of the device. Full prescribing information is
available at www.optune.com/safety
or by calling toll free 1-855-281-9301 in the US or by email at supportEMEA@novocure.com
in the European Union.

Important Safety Information

Contraindications: Do not use Optune if you have an active
implanted medical device, a skull defect (such as, missing bone with no
replacement), or bullet fragments. Use of Optune together with implanted
electronic devices has not been tested and may theoretically lead to
malfunctioning of the implanted device. Use of Optune together with
skull defects or bullet fragments has not been tested and may possibly
lead to tissue damage or render Optune ineffective.

Do not use Optune if you are known to be sensitive to conductive
hydrogels. In this case, skin contact with the gel used with Optune may
commonly cause increased redness and itching, and rarely may even lead
to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions: Use Optune only after receiving
training from qualified personnel, such as your doctor, a nurse, or
other medical personnel who have completed a training course given by
Novocure (the device manufacturer).

Do not use Optune if you are pregnant, you think you might be pregnant
or are trying to get pregnant. It is not known if Optune is safe or
effective in these populations.

The most common (≥10%) adverse events involving Optune in combination
with temozolomide were low blood platelet count, nausea, constipation,
vomiting, fatigue, scalp irritation from device use, headache,
convulsions, and depression.

The most common (≥10%) adverse events seen when using Optune alone were
scalp irritation from device use and headache.

The following adverse reactions were considered related to Optune when
using the device alone: scalp irritation from device use, headache,
malaise, muscle twitching, fall and skin ulcer.

All servicing procedures must be performed by qualified and trained
personnel.

Do not use any parts that do not come with the Optune Treatment Kit, or
that were not sent to you by the device manufacturer or given to you by
your doctor.

Do not wet the device or transducer arrays.

If you have an underlying serious skin condition on the scalp, discuss
with your doctor whether this may prevent or temporarily interfere with
Optune treatment.

Please see http://www.optune.com/safety
to see the Optune Instructions For Use (IFU) for complete information
regarding the device's indications, contraindications, warnings, and
precautions.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure's current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning. Novocure's performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.

View Comments and Join the Discussion!